Computational and Biological Evaluation of N-octadecyl-N′-propylsulfamide, a Selective PPARα Agonist Structurally Related to N-acylethanolamines

Elaidyl-sulfamide, an oleoylethanolamide-modelled PPAR  agonist, reduces body weight gain and plasma cholesterol in rats

(2012) J. M. Decara et al.   Disease Models & Mechanisms

Effects of the anandamide uptake blocker AM404 on food intake depend on feeding status and route of administration

(2011) Carmen Reyes-Cabello et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Biological Functions and Metabolism of Oleoylethanolamide

(2008) Clémentine Thabuis et al.   LIPIDS

Fibrates and future PPARα agonists in the treatment of cardiovascular disease

(2008) Bart Staels et al.   Nature clinical practice. Cardiovascular medicine

Antitumor studies – Part 2: Structure–activity relationship study for flavin analogs including investigations on their in vitro antitumor assay and docking simulation into protein tyrosine kinase

(2007) Hamed I. Ali et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats

(2007) Antonia Serrano et al.   NEUROPHARMACOLOGY